The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

• Главные авторы: Hélène Haguet (Автор), Céline Bouvy (Автор), Anne-Sophie Delvigne (Автор), Elise Modaffari (Автор), Adeline Wannez (Автор), Pierre Sonveaux (Автор), Jean-Michel Dogné (Автор), Jonathan Douxfils (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2020-07-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, inc...